This study has focused on enhancing the signal generated from the interaction between a G-protein-coupled receptor (GPCR) and β-arrestin 2 (β-arr2), measured by the bioluminescence resonance energy transfer (BRET 2 ) technology. Both class A (β 2 -adrenergic receptor [β 2 -AR]) and class B (neurokinin-type 1 receptor [NK1-R]) GPCRs, classified based on their internalization characteristics, have been analyzed. It was evaluated whether the BRET 2 signal can be enhanced by using (1) β-arr2 phosphorylation-independent mutant (β-arr2 R169E) and (2) β-arr2 mutants deficient in their ability to interact with the components of the clathrin-coated vesicles (β-arr2 R393E,R395E and β-arr2 373 stop). For the class B receptor, there was no major difference in the agonist-promoted BRET 2 signal when comparing results obtained with wild-type (wt) and mutant β-arr2. However, with the class A receptor, a more than 2-fold increase in the BRET 2 signal was observed with β-arr2 mutants lacking the AP-2 or both AP-2 and clathrin binding sites. This set of data suggests that the inability of these β-arr2 mutants to interact with the components of the clathrin-coated vesicle probably prevents their rapid dissociation from the receptor, thus yielding an increased and more stable BRET 2 signal. The β-arr2 R393E,R395E mutant also enhanced the signal window with other members of the GPCR family (neuropeptide Y type 2 receptor [NPY2-R] and TG1019 receptor) and was successfully applied in full-plate BRET 2 -based agonist and antagonist screening assays. (Journal of Biomolecular Screening 2004:322-333) The use of the β-arr mutants with reduced affinity for components of the clathrincoated pit in BRET assays requires a license from 7TM Pharma.
INTRODUCTION
G -PROTEIN-COUPLED RECEPTORS (GPCRs), also called 7 transmembrane receptors (7TM receptors), form the largest receptor family encoded by the human genome and mediate cellular responses to a plethora of endogenous ligands. GPCRs are also targets for more than 30% of clinically marketed drugs, thus making this receptor family the largest target family for drug discovery. 1 Improvements in the drug discovery process have mainly encompassed development of new methods and technological innovation, including automation and miniaturization. 2 In the GPCR field, cell-based functional screening assays offer significant advantages over classical receptor binding assays, which cannot differentiate between agonists and antagonists and result in many false hits. 2 The basic model for signal transduction mediated by GPCRs comprises a receptor, a heterotrimeric G-protein, and an effector protein. Thus, functional cell-based screening on GPCRs is based on activation of specific signal transduction pathways via coupling to 3 different classes of G-proteins (i.e., G αs , G αi/0 , or G αq/11 ). This means that at least 3 distinct assays are currently needed to screen GPCRs in a functional cell-based way. There has therefore long been a wish for a universally applicable functional cell-based screening assay that could be used to screen all receptors independent of their signaling pathway.
Agonist-mediated arrestin translocation by GPCRs is an almost universal event, which has been shown to occur with the vast majority of GPCRs independent of their signaling pathway (for review, see Claing et al. 3 and Perry and Lefkowitz 4 ). Despite the common occurrence of this interaction, differences in receptor affinities for nonvisual arrestins (β-arrestin-1 and β-arrestin-2, also termed arrestin-2 and arrestin-3) and their ability to remain in complex with β-arrestins (β-arrs) after internalization exist, thus delineating 2 major receptor classes (classes A and B), as schematically shown in Figure 1 . 5 After agonist stimulation, the class A receptors (e.g., β 2 -adrenergic receptor [β 2 -AR], dopamine D1A receptor, and α 1b adrenergic receptor) recruit β-arr2 more efficiently than β-arr1 but then rapidly dissociate from the β-arr just after internalization in the vicinity of the plasma membrane. In contrast, the class B receptors, including the neurokinin type 1 (NK1-R), vasopressin type 2 (V2R), angiotensin II type 1A, and type I thyrotropin-releasing hormone receptors, recruit both β-arrs equally well and remain bound to the β-arrs for a prolonged time period after internalization. 5 Determinants within the receptors, as well as β-arrs, underlie the stability of the formed receptor/arrestin complex. 6 Conserved residues within the C-terminal end of the βarrs are essential for interaction with the heavy chain of clathrin 7, 8 and the β 2 -adaptin subunit of the clathrin-associated adaptor protein complex AP-2. 9-11 β-arr2 displayed stronger interaction with these endocytic proteins compared to β-arr1. 9 Therefore, an assay based on the agonist-promoted receptor/β-arr2 interaction integrated into a suitable technological platform has the potential to be turned into a universal, functional screening assay for GPCRs.
In recent years, biophysical methods based on fluorescence and bioluminescence resonance energy transfer (FRET and BRET, respectively) have been developed. These techniques enable monitoring of physical interactions between 2 proteins fused to FRET/ BRET donor and acceptor moieties, respectively, dependent on their intermolecular distance (10-100 Å) and on relative orientation. 12 Although FRET enables the visualization of protein interactions in living cells, the problems associated with FRET (e.g., high-fluorescent background, autofluorescence, photobleaching) make BRET the technology of choice for several applications. BRET methodology was first described in a study on dimerization of the bacterial Kai B clock protein. 13 Subsequently, BRET was introduced in the GPCR and tyrosine kinase receptor field, demon-strating β 2 -AR dimerization and agonist-promoted β 2 -AR/β-arr2 complex formation, 14 as well as ligand-induced conformational changes in the insulin receptor. 15 Since then, the existence of homodimers and heterodimers between several GPCRs has been reported in living cells (for review, see Angers et al. 16 ). The BRET 2 / arrestin assay has also been suggested as a suitable tool for characterization of ligand-GPCR interactions. 17 Possible applications of these emerging techniques for basic research and for the drug discovery process have recently been reviewed by Eidne et al. 18 and Boute et al. 19 In the present study, we employed the BRET 2 methodology to detect and manipulate the BRET signal generated from agonistinduced interaction between different receptors and β-arr2 constructs. In BRET 2 assays, Renilla luciferase (Rluc) is used as the donor and the green fluorescent protein (GFP) variant GFP 2 as the acceptor molecule. Upon addition of the substrate DeepBlueC™, a coelenterazine analog in which the emission spectrum is shifted to shorter wavelengths, Rluc emits blue light peaking at 395 nm. When the GFP 2 -tagged acceptor molecule, adapted to this emission wavelength, is in close proximity to a Rluc-tagged donor molecule, excitation of GFP 2 occurs by resonance energy transfer (RET), resulting in emission of green light at 510 nm. This modified BRET pair results in a broader Stokes shift of 115 nm, compared to the approximately 50-nm Stokes shift obtained in previously described BRET systems. 20 The improved Stokes shift results in a better separation of the Rluc and GFP light and therefore higher sensitivity. The resulting BRET 2 signal is then deter-mined ratiometrically as a 510/395 ratio. So far, it has not been possible to use the BRET 2 technology for screening of full 96-well plates due to lack of suitable instrumentation (poor detection and no online injectors) and due to biological obstacles (class A receptors give low BRET signals). Therefore, we investigated the possibility of improving the BRET 2 signal for members of the class A (exemplified by the β 2 -AR) and class B (exemplified by the NK1-R) receptors C-terminally tagged with Rluc and human β-arr2 constructs N-terminally tagged with GFP 2 . We evaluated the effect of a β-arr2 phosphorylation-independent mutant (β-arr2 R169E) and β-arr2 mutants deficient in their ability to interact with the components of the clathrin-coated vesicles (β-arr2 R393E,R395E and β-arr2 373 stop) on the BRET 2 signal and tested the applicability of the β-arr2 constructs in a BRET 2 -based functional screening assay.
MATERIALS AND METHODS

Renilla luciferase (Rluc) and green fluorescent protein (GFP 2 ) fusion constructs
Human β-arr2 N-terminally tagged with GFP 2 (GFP 2 /β-arr2) and GFP 2 -Rluc were purchased from BioSignal Packard, Inc. (Montreal, Canada). The C-terminally tagged Rluc-receptor constructs (NK1-R/Rluc, β 2 -AR/Rluc, neuropeptide Y type 2 receptor/ Rluc [NPY2-R/Rluc], and TG1019 receptor/Rluc [TG1019-R/ Rluc]) were made using standard molecular biology techniques. Mutations Arg 169 → Glu, Arg 393,395 → Glu, and Leu 373 → stopcodon were introduced individually in human GFP 2 /β-arr2 using the QuickChange site-directed mutagenesis kit from Stratagene (La Jolla, CA). All cDNA clones were verified by sequencing.
Cell culture and transfection
COS-7 and HEK-293 cells were obtained from the European Collection of Animal Cell Cultures (Salisbury, UK). HEK-293 cells were routinely maintained and passaged in minimum essential medium (MEM) supplemented with 10% (v/v) heatinactivated fetal calf serum (HIFCS), 2 mM Glutamax™-I, 1% NEAA, 1% NaPyr, and 10 µg/mL gentamicin. COS-7 cells were routinely maintained and passaged in complete Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% (v/v) fetal calf serum (FCS), 2 mM Glutamax™-I, and 10 µg/mL gentamicin. The COS-7 and HEK-293 cells were incubated at 37°C in a humidified atmosphere of 10% and 5% (v/v) CO 2 in air, respectively. For transient transfection, COS-7 and HEK-293 cells were seeded at a density of 3 × 10 6 cells and 4 × 10 6 cells per 75-cm 2 flask, and transfections were performed the following day using Lipofectamine™. The optimal receptor/arrestin ratio was determined for each receptor construct. Using trypsin, cells were harvested 48 h after transfection and then washed twice in phosphatebuffered saline (PBS). The cell number was determined using a coverslipped hemocytometer, and cells were resuspended in Dulbecco's PBS supplemented with glucose to a density of 2 × 10 6 cells/mL. All the tissue culture media and reagents were purchased from Gibco Invitrogen Corporation (Breda, The Netherlands) unless otherwise specified.
BRET 2 assay
We developed the protocol for BRET 2 measurements using the Mithras LB 940 plate reader equipped with 4 injectors (Berthold Technologies, Bad Wildbad, Germany). Briefly, following harvesting, 100 µL of resuspended cells containing~200,000 cells was distributed to wells in 96-well microplates (white Optiplate; Packard BioScience, Montreal, Canada) by the Mithras injector 1. For an agonist screening, injectors 2 and 3 simultaneously injected agonist and the substrate DeepBlueC™ (final concentration 5 µM; BioSignal Packard, Inc., Montreal, Canada). For an antagonist assay, the (potential) antagonist was injected using injector 4 to preselected wells prior to the simultaneous injection of agonist and substrate. Readings were then collected 2 sec after the final injections. The signals detected at 395 nm and 515 nm were measured sequentially, and the 515/395 ratios were calculated and expressed as a miliBRET level (BRET ratio × 1000).
Luminescence and fluorescence measurement
Expression levels of Rluc-and GFP 2 -tagged constructs for each BRET 2 experiment were monitored by luminescence and fluorescence measurements. For a luminescence measurement, cells resuspended in glucose-supplemented Dulbecco's PBS were seeded in 96-well microplates (white Optiplate; Packard BioScience, Inc., Montreal, Canada) at a density of~5 × 10 4 cells per well. After 1 h incubation and before measuring, DeepBlueC™ (BioSignal Packard, Inc., Montreal, Canada) was added at a final concentration of 5 µM, and total luminescence was measured using the TopCount microplate reader (Packard BioScience, Inc., Montreal, Canada). For a fluorescence measurement, the cells from the same transfections were plated in black clear-bottom microplates (ViewPlate; Packard BioScience, Inc., Montreal, Canada) at a density of~5 × 10 4 cells per well. After 1 h incubation in darkness, the total fluorescence was measured using the NovoStar microplate reader (BMG LabTech, Offenburg, Germany), with an excitation line at 485 nm and an emission filter at 520 nm. Background values obtained with untransfected cells were subtracted in both measurements, and the means of triplicate wells/sample were then calculated.
Receptor binding assay
Assays were performed 48 h after transfection. To check if a linear relationship exists between the luminescence signal generated by Rluc-tagged NK1-Rs and the cell-surface receptor number, we carried out radioligand binding assays on whole cells. After transfections with an increasing amount of cDNA for NK1-R/ Rluc, cells were plated into 24-well plates at a density of~1 × 10 5 cells per well. An aliquot of cells (~5 × 10 5 ) from each transfection was also transferred into a 60-mm dish for luminescence measure-ments. For the dose-response radioligand binding assay, cells were washed once with assay buffer (HEPES-modified DMEM with 0.1% bovine serum albumin [BSA]) before being incubated with [ 125 I]-labeled Substance P ([ 125 I]-SP; Amersham Biosciences, Little Chalfont, UK) (30,000 cpm/well) and the increasing concentration of either unlabeled Substance P (10 -12 to 10 -6 M final concentration) or nonpeptide NK1-R antagonists (CP96,345 or SR140,333) in a 0.5-mL assay buffer for 3 h at 4°C. Cells were then washed 3 times in 0.5 mL ice-cold PBS, solubilized with 1 mL 0.2 M NaOH and 1% sodium dodecyl sulfate (SDS) solution, and the radioactivity was counted. The same protocol was used for the β 2 -AR binding assay using the β-adrenergic antagonist [ 125 I]iodopindolol (PerkinElmer, Wellesley, MA, USA). Binding parameters were determined from displacement curves generated by sigmodial dose-response curve fit (GraphPad Prism). Receptor density, expressed as receptor number per cell, was calculated as previously described by Ramsay et al. 21 
Ca 2+ assay
Changes in intracellular free Ca 2+ concentration after NK1-R agonist activation was measured using the NovoStar microplate reader (BMG LabTech, Offenburg, Germany), as previously described. 22 Receptor internalization assay NK1-R internalization assay based on the acid-wash method was performed as described previously. 23 The effect of GFP 2 /β-arr2 mutants on the NK1-R internalization was assessed using [ 125 I]-SP (Amersham Biosciences, Little Chalfont, UK) as tracer. β 2 -AR internalization was induced by 10 µM isoproterenol at 37°C
. Receptor sequestration was then defined as the fraction of specific hydrophobic [ 125 I]-iodopindolol (PerkinElmer, Wellesley, MA, USA) binding not displaced by hydrophilic ligand (CGP-12177), as previously described by Barak and Caron. 24 
RESULTS
Characteristics of NK1-R and 2 -AR fusion constructs
Pharmacological characterization of the NK1-R C-terminally tagged with Renilla luciferase (NK1-R/Rluc) was done by radioligand binding assays and Ca 2+ measurements. In selfcompetition assays performed in COS-7 cells expressing the NK1-R/Rluc, SP competed for binding against the [ 125 I]-SP with an affinity of 0.42 ± 0.16 nM (Table 1 ). IC 50 values of 0.34 and 0.39 nM were obtained for antagonists CP96,345 and SR140,333, respectively, in competition binding assays (data not shown). These values are comparable to those previously published for wild-type human NK1-R. 25 An EC 50 value of 3.27 nM for the SP-induced Ca 2+ response was also determined for NK1-R/Rluc (data not shown). This value corresponds well with previously published values for wild-type human NK1-R SP-induced Ca 2+ release, 22 as well as SPinduced inositol phosphate and cyclic adenosine monophosphate (cAMP) accumulation. 25 In competition binding assays, the IC 50 (0.94 ± 0.06 nM) of pindolol on the β 2 -AR/Rluc was in the range reported for β 2 -AR fusion constructs. 14, 26 The binding characteristics of the tagged and untagged receptors are summarized in Table  1 . Moreover, the potency of ligand-induced interactions between either the NK1-R/Rluc or the β 2 -AR/Rluc with the GFP 2 /β-arr2 constructs using the BRET 2 assay was comparable to data obtained in radioligand and second-messenger assays (see Table 2 and Fig.  8 ). The obtained BRET 2 EC 50 values for agonist-induced β-arr2/ β 2 -AR interaction are also in good agreement with the data reported for the same receptor using the Transfluor™ arrestin recruitment assay. 27 
Monitoring the expression levels of fusion constructs
Total luminescence and fluorescence were measured before each BRET 2 experiment to monitor the expression levels of Rlucand GFP 2 -tagged constructs. The linear correlations obtained between the number of the cell surface receptor binding sites and the total luminescence, as well as the amount of GFP 2 /β-arr2 cDNA and the total fluorescence, are shown in Figure 2 . Based on these measurements, the luminescence/fluorescence (L/F) ratio resulting in the optimal BRET 2 ratio was estimated. The amount of receptor/Rluc and GFP 2 /β-arr2 constructs used in transfections was then standardized to achieve the L/F ratio of 2.5 to 3, which resulted in the optimal BRET 2 signal under our experimental conditions.
BRET 2 signal: class A versus class B receptor
We initially tested whether the agonist-stimulated interaction between β-arr2 and members of the class A and class B receptors results in comparable BRET 2 signals. As depicted in Figure 3 , an agonist-dependent increase in the BRET 2 signal generated by the β-arr2 interaction with NK1-R, a member of the class B receptor, was markedly higher (about 4-fold) compared to the β 2 -AR (class A receptor). An EC 50 of 8.0 nM and 39.2 nM was calculated from BRET 2 agonist dose-response curves for the NK1-R (SP) and β 2 -AR (isoproterenol), respectively.
BRET 2 signal: effect of -arr2 mutants
In an attempt to improve the BRET 2 signal for class A receptors, we generated β-arr2 mutants that either bind to the receptor independent of its phosphorylation status (β-arr2 R169E) 28 or lack the ability to interact with components of the clathrin-coated vesicles (β-arr2 R393E,R395E and β-arr2 373 stop). β-arr2 R393E,R395E does not bind AP-2 and has diminished affinity for clathrin, 29, 30 The β-arr2 fusion proteins were validated by a receptor/ligand internalization assay in COS-7 cells. Marked difference in the internalization kinetics between the NK1-R/Rluc and β 2 -AR/Rluc was observed, which is in agreement with previously published internalization data for the untagged receptors 29, 32, 33 (Fig. 4) . The β-arr2 R169E mutant had no profound effect on the internalization of either receptor type, although a decrease of approximately 17% compared to wild-type (wt) β-arr2 was observed for the NK1-R. β-arr2 373 stop and β-arr2 R393E,R395E reduced the percentage of total internalized NK1-R by about 52% and 42%, respectively. β-arr2 373 stop and β-arr2 R393E,R395E also diminished the internalization of the β 2 -AR significantly (see Fig. 4 ). The function of the β-arr2 fusion proteins was also validated by confocal microscopy (data not shown).
As the biological activity of the GFP 2 /β-arr2 mutants, with respect to the effect on internalization and the ability to translocate to the plasma membrane after receptor activation, indicated a reduced interaction with components of the clathrin-coated pit, we then wished to investigate whether they had the ability to improve BRET 2 signals. β-arr2 mutants had no significant effect on the agonist-promoted BRET 2 signal obtained with the NK1-R (Fig. 5 ). However, agonist-promoted interaction of the β 2 -AR with either β-arr2 373 stop or β-arr2 R393E,R395E resulted in more than a 2-fold increase (2.2 ± 0.28 and 2.3 ± 0.12 for β-arr2 373 stop and β-arr2 R393E,R395E, respectively) in the BRET 2 signal when compared to wt β-arr2 (Fig. 5 ). The effectiveness of the phosphorylation-independent mutant β-arr2 R169E in comparison with wt β-arr2 was only slightly improved, with an increase of only 1.3-fold (1.3 ± 0.20) (see Fig. 5 ). Although no significant differences were observed between β-arr2 373 stop and β-arr2 R393E,R395E, we selected the β-arr2 R393E,R395E mutant for further investigations. We tested the effectiveness of this mutant with other members of the GPCR family, evaluated the effect of the cell type on the 
FIG. 5. Effect of β-arr2 mutants on bioluminescence resonance energy transfer (BRET 2
) signals generated by agonist-induced green fluorescent protein (GFP 2 )/β-arr2 construct interaction with either neurokinin-type 1 receptor (NK1-R) or β 2 -AR. COS-7 cells transiently transfected with GFP 2 /β-arr2 mutants together with either NK1-R/Renilla luciferase (Rluc) or β 2 -AR/Rluc were treated with SP or isoproterenol, and BRET 2 was measured as described in Material and Methods. Data represent the mean ± SEM for a single experiment carried out in triplicate and are representative of a total of 3 independent experiments. size of the BRET 2 signal, generated agonist and antagonist doseresponse curves, and performed BRET 2 -based functional screening assays.
The efficacy of the β-arr2 R393E,R395E mutant was again demonstrated with 2 other members of the GPCR family: the NPY2-R and the recently cloned G i/o -coupled eicosanoid receptor, denoted as TG1019. 34 The β-arr2 R393E,R395E mutant increased the agonist-induced BRET 2 signal window by 1.74 ± 0.14-fold and 3.33 ± 0.20-fold for the NPY2-R and the TG1019-R, respectively (Fig. 6 ).
BRET 2 signal: COS-7 versus HEK-293 cells
The effect of different expression levels of endogenous βarrestins on the BRET 2 signals was examined in COS-7 and HEK-293 cells. The expression level of endogenous β-arrs is relatively lower in COS-7 cells compared to HEK-293 cells. 35 The BRET 2 signal obtained in HEK-293 was significantly lower than in COS-7 
FIG. 7.
Characterization of the β-arr2 R393E,R395E mutant in comparison to wt β-arr2 in inducing the bioluminescence resonance energy transfer (BRET 2 ) signal in COS-7 and HEK-293 cells generated by agonist-induced interaction with either the neurokinin-type 1 receptor (NK1-R) or β 2 -AR. Increasing concentrations of the agonists Substance P (SP) or isoproterenol were added to cells transiently transfected with either NK1-R/Renilla luciferase (Rluc) or β 2 -AR/Rluc and the indicated expression constructs. BRET cells (Fig. 7) . Agonist-promoted BRET 2 signals generated from NK1-R interactions with either the wt β-arr2 or the β-arr2 R393E,R395E mutant were about 40% (38.3% ± 1.4%) lower in HEK-293 when compared to COS-7 cells. For the β 2 -AR, a reduction of the BRET 2 signal by only 10% was observed with wt β-arr2 in HEK-293 cells compared to COS-7 cells, whereas a more significant decrease in BRET 2 signal (44.2% ± 7.2%) was observed for the β 2 -AR/β-arr2 R393E,R395E interaction. Calculated EC 50 values from the BRET 2 agonist dose-response curves obtained for either the NK1-R or β 2 -AR and the individual β-arr2 constructs in both cell types are summarized in Table 2 . Figure 8 shows the BRET 2 antagonist dose-response curves generated in the presence of an increasing concentration of either the NK1-R antagonist CP96,345 or the adrenergic receptor antagonist pindolol. The potency of CP96,345 (IC 50 = 0.47 nM) was similar to that obtained in receptor binding assays. The same was observed for the β 2 -AR antagonist pindolol (IC 50 = 0.93 nM). Using the arrestin recruitment assay, a comparable IC 50 of 0.69 nM was reported for another β 2 -AR antagonist, propranolol. 27 
Screening assays
As the BRET 2 signal obtained for the NK1-R and β 2 -AR using the β-arr2 R393E,R395E mutant resulted in robust agonist and antagonist dose-response curves with pharmacology similar to that found in other assays, we also tested the applicability of this mutant in BRET 2 -based agonist and antagonist screening assays. To perform agonist screening assays, we injected the agonist (SP or isoproterenol) to selected wells in 96-well plates containing cells expressing either NK1-R/Rluc and GFP 2 /β-arr2 R393E,R395E or β 2 -AR/Rluc and GFP 2 /β-arr2 R393E,R395E. Wells injected with agonist were clearly detected as the wells with the highest BRET 2 signal (see Fig. 9 ). We screened 2 consecutive plates in agonist mode for the NK1-R and 3 consecutive plates for the β 2 -AR. Z′ values for the NK1-R assay ranged from 0.50 to 0.70 and, for the β 2 -AR Z′, ranged from 0.54 to 0.60. For antagonist screening assays, 2 different antagonists were used for each receptor. For the NK1-R, antagonists used were SR140,333 and CP96,345, and pindolol and alprenolol were used as antagonists for the β 2 -AR. The individual antagonists were first added to selected wells containing the relevant cells. The appropriate agonist (SP or isoproterenol) and substrate were then injected simultaneously and the BRET 2 signal measured. We screened 2 consecutive plates in antagonist mode for the NK1-R and 3 consecutive plates for the β 2 -AR. Because a hit is defined on the basis of the point at which inhibition becomes statistically significant, the planted hits are easily detected as the wells with the lowest BRET 2 ratio (see Fig. 10 ). Z′ values for the NK1-R assay ranged from 0.62 to 0.76 and, for the β 2 -AR Z′, ranged from 0.51 to 0.59.
DISCUSSION
The growing number of drug targets and the complexity of the intracellular events following ligand-receptor interaction represent a pressing demand and a technological challenge for the development of a generally applicable functional cell-based screening platform. A range of assays has been developed for monitoring Gprotein activation, receptor trafficking, receptor dimerization/ oligomerization, and downstream signaling events. 36 In the present study, we employed the BRET 2 technology to monitor the agonistinduced GPCR/β-arr2 interaction with known class A and class B receptors exemplified by β 2 -AR and NK1-R, as well as the NPY2 and TG1019 receptors. Initially, it was observed that the agonist- /β-arr2 R393E,R395E. To the remaining wells, substrate and buffer were injected using injectors 2 and 4. SP was injected to 5 wells in the NK1-R plates, and isoproterenol was injected to 6 wells in the β 2 -AR plates. Data shown are mean ± SEM of duplicate/triplicate observations. The planted "hits" are indicated by arrows. . 10 . Antagonist screening assays for the neurokinin-type 1 receptor (NK1-R) and β 2 -AR. A total of 100 µL of resuspended cells containing 200,000 cells were distributed in 96-well microplates by the Mithras injector 1. NK1-R antagonists SR140,333 (1) and CP96,345 (2) were added to selected wells individually in 96-well plates containing COS-7 cells transiently transfected with NK1-R/Renilla luciferase (Rluc) and green fluorescent protein (GFP 2 )/β-arr2 R393E,R395E. In the same way, β 2 -AR antagonists pindolol (3) and alprenolol (4) were added to selected wells in 96-well plates containing COS-7 cells transiently transfected with β 2 -AR/ Rluc and GFP 2 /β-arr2 R393E,R395E. All antagonists were used at a final concentration of 1 µM. The substrate (final concentration 5 µM) and the relevant agonist (Substance P [SP] or isoproterenol; final concentration 1 µM) were then simultaneously injected by injectors 2 and 3 to all wells. Data shown are mean ± SEM of duplicate/triplicate observations. The planted "hits" are numbered for each antagonist and indicated by arrows. vine β-arr1 and 2, respectively, and to the R175E in visual arrestin) reverses the charge of a critical amino acid within the arrestin polar core, thus making its binding to the receptor phosphorylation independent. 28, 38, 39 Conserved residue R395 is important for interaction with the β 2 -adaptin subunit of the AP-2 complex, 10, 30 whereas the R393 (homolog of R382 in visual arrestin) is an integral part of the polar core and is also predicted to be part of the AP-2 binding site. 30, 31 Reversing or neutralizing the charge of this amino acid should destabilize the polar core and yield a phosphorylation-independent mutant as already demonstrated for β-arr2 R393Q. 28 The β-arr2 373 stop mutant does not have the regulatory arrestin carboxyl terminus, which keeps arrestin in a basal conformation, as well as both AP-2 and clathrin binding domains. 31 Biological activity of the GFP 2 -tagged β-arr2 mutants was tested in internalization experiments. NK1-R internalization data largely recapitulate the results of McConalogue et al. 40, 41 and Schmidlin et al. 33 The effect of the dominant-negative β-arr 319-418 mutant on NK1-R internalization has been previously described, 33 whereas the effect of similar/analogous mutants to the ones we used has not been evaluated on the NK1-R internalization. The relative large negative effect on NK1-R internalization by the mutants lacking the AP-2 or AP-2 and clathrin binding domains was anticipated. A recent in vitro finding shows that the homologous mutant in the β-arr1 (R169E) has enhanced binding to β 2 -adaptin and clathrin. 29 However, the small decrease in NK1-R internalization mediated by the R169E mutant could be explained by another recent finding describing that receptors in complex with the β-arr1 R169E mutant recycle faster than receptors in complex with wt β-arr1. 42 The internalization results obtained for the β 2 -AR are in agreement with previously published data showing that the β-arr1 R169E mutant supports β 2 -AR internalization. 42 Mutants in bovine β-arr1 R395E and LIELD/R395E with disrupted AP-2 or both clathrin and AP-2 interaction sites, respectively, reduced the β 2 -AR internalization in COS-1 cells to a similar extent as observed here with the β-arr2 mutants. 29 The absence of any significant effect of the β-arr2 mutants on the BRET 2 signal observed for the NK1-R is probably due to the ability of this receptor to form stable complexes with wt βarrs. 6 Because phosphorylation-independent β-arr2 mutants bind to the activated form of the receptor, it seems that NK1-R phosphorylation is not a limiting step for β-arr2 binding, not even in COS-7 cells with relatively low endogenous expression of G-protein-coupled receptor kinases (GRKs). 35 In contrast, β-arr2 mutants improved the agonist-promoted BRET 2 signal with the β 2 -AR as well as with 2 other members of the GPCR family, the NPY2-R and TG1019-R. The β 2 -AR kinase-mediated phosphorylation has been shown as a rate-limiting factor for βarrestin-promoted internalization. 43 An activated-unphosphorylated receptor should then serve as a good substrate for the β-arr2 R169E mutant. However, only a moderate increase was observed, which suggested that making the receptor-arrestin interaction phosphorylation independent is not sufficient to obtain robust BRET 2 signals. Thus, we disrupted interaction sites between β-arr2 and β 2 -adaptin and/or clathrin to prolong/enhance the otherwise low-affinity interaction between class A receptors and β-arrs. Preventing the interaction of the receptor/β-arr2 complex with components of the clathrin-coated pit should therefore prolong the lifetime of the receptor/β-arr2 complex, resulting in an enhanced BRET 2 signal. Disruption of the β-arr2/AP-2 binding (R395E) and reversing the charge of an amino acid in the polar core (R393E) 30 resulted in a substantially increased BRET 2 ratio. Additional removal of the clathrin binding domain did not result in a cumulative effect on the BRET 2 ratio, in accordance with the suggestion that AP-2 interaction precedes binding to clathrin. 10 The higher BRET 2 ratio obtained in COS-7 compared to HEK-293 cells could be explained by the low endogenous β-arrs level in COS-7 cells 35 and consequent reduced competition with tagged β-arrs. As the pharmacological characterization of the receptor/β-arr2 mutants interaction by BRET 2 resulted in pharmacology comparable to that observed in other assays, we were able to establish screening assays based on this technology. The BRET 2 signal obtained for the NK1-R and β 2 -AR screening assays using the β-arr2 R393E,R395E mutant resulted in robust signals with high Z′ values. 2 The BRET technology has been used in the past to measure the receptor/β-arr interaction in living cells, 14, 17, 44 but due to various technical and biological reasons, it has previously not been possible to apply the technology to medium/high-throughput screening (MTS/HTS). Here we described the use of the novel BRET reader equipped with online injectors and increased sensitivity. The use of online injectors is essential because the half-life (t 1/2 ) of the reaction between DeepBlueC™ and Rluc is very short (e.g., for the assay described here, the optimal reading time after DeepBlueC™ injection is 2 sec; unpublished observation). We found that the combination of the described instrumentation and β-arr2 mutants allowed us to performed full-plate screening assays.
FIG
The BRET 2 arrestin/receptor assay described holds many advantages over the existing functional cell-based screening assays. The assay is virtually universally applicable and is therefore both time and resource efficient, as different assays and instruments do not need to be established or acquired. In addition, the assay is ratiometric (not influenced by variations in cell number/ well) and is based on luminescence. This is an advantage over the fluorescence-based assays often associated with autofluorescence problems. The number of false hits is also considerably reduced compared to other functional assays. In those assays, compounds often directly interact with the effector molecules in the signaling pathway and result in false hits. Another technology platform based on the same arrestin-receptor interaction is the Transfluor™ assay. 27 Although this technology shares many of the advantages of the above-described assay, its main shortcoming is the cost connected with its implementation (high licensing fees and complex/expensive instrumentation). The modified BRET 2 assay described here should therefore be an attractive alternative to existing functional cell-based screening assays, offering a robust and universally applicable assay.
